PON1 and hepatocellular carcinoma: Our previous study along with others suggests a compelling serological biomarker potential for fucosylated PON1 in advanced SCLC and early HCC (Ahn et al., 2014; Aldonza et al., 2017; Sun et al., 2012; Zhang et al., 2015).